TrialSignal
Clinical trial intelligence report
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03761914
Status
COMPLETED
Phase
PHASE1
Sponsor
Sellas Life Sciences Group
Executive brief
Investment-Ready Snapshot
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03761914
Indication
Acute Myelogenous Leukemia
Modality
monoclonal antibody
Target
galinpepimut-S, pembrolizumab, Montanide, GM-CSF
Intervention
galinpepimut-S, pembrolizumab, Montanide, GM-CSF
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.